|Mr. Vijay B. Samant||Chief Exec. Officer, Pres and Director||905.94k||N/A||64|
|Mr. Anthony Alan Ramos||Chief Financial Officer & Principal Accounting Officer||336.63k||N/A||50|
|Dr. Lawrence Russell Smith Ph.D.||Sr. VP of Research||360.95k||N/A||56|
|Mr. Keith D. Hall M.D.||VP of Operations||N/A||N/A||55|
|Dr. Mammen P. Mammen Jr., M.D.||Sr. VP of Clinical Devel.||N/A||N/A||53|
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the companys core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.
Vical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.